|
|
|
|
Aurobindo Pharma gets nod for seizure drug
Aurobindo Pharma Ltd said on Monday it got approval for its abbreviated new drug submission for topiramate tablets from Health Canada.Topiramate tablet is the generic equivalent of Canadian firm Janssen-Ortho Inc's Tapomax tablets, it said in a...
|
|
|
Aurobindo Pharma spurts on bagging nod for Topiramate Tablets from Health Canada
Aurobindo Pharma has bagged the approval for its abbreviated New Drug Submission for Topiramate tablets 25 mg as well as 50 mg, 100 mg and 200 mg from health Canada.Topiramate tablets 25 mg as well as 50 mg, 100 mg and 200 mg is the generic equivalent of...
|
|
|
Aurobindo gets Canadian nod for for Topiramate Tablets
Aurobindo Pharma, a Hyderabad-based pharma maker has received the approval for its Abbreviated New Drug Submission for Topiramate Tablets 25mg, 50mg, 100mg & 200mg from Health Canada.Aurobindo said Topiramate Tablet 25mg, 50mg, 100mg & 200mg...
|
|
|
Aurobindo Pharma gets nod for seizure drug
MUMBAI, March 22 - Aurobindo Pharma Ltd ARBN.BO said on Monday it got approval for its abbreviated new drug submission for topiramate tablets from Health Canada.Topiramate tablet is the generic equivalent of Canadian firm Janssen-Ortho Inc's Tapomax...
|
|
|
Aurobindo Pharma gets nod for seizure drug
Aurobindo Pharma Ltd said on Monday it got approval for its abbreviated new drug submission for topiramate tablets from Health Canada.Topiramate tablet is the generic equivalent of Canadian firm Janssen-Ortho Inc's Tapomax tablets, it said in a...
|
|
|
Aurobindo Pharma gets nod for seizure drug
Topiramate tablet is the generic equivalent of Canadian firm Janssen-Ortho Inc's Tapomax tablets, it said in a statement to the BSE.Aurobindo Pharma gets nod for seizure drug.
|
|
|
Pediatric Exclusivity Granted
Drugs to Which FDA has Granted Pediatric Exclusivity for Pediatric Studies under Section 505A of the Federal Food, Drug, and Cosmetic Act NOTE: This list simply identifies approved active drugs with sponsors to which FDA has granted exclusivity for pediatric...
|
|
|
High Stakes, Huge Money
As with any practice, victory in IP litigation can be defined a number of ways.Perhaps it comes in the form of a multimillion-dollar jury verdict. Or as a judge's ruling affirming the validity of the patent on a blockbuster drug. Or as an injunction that...
|
|
|
Photocaged T7 RNA Polymerase for the Light Activation of Transcription and Gene Function in Pro- and Eukaryotic Cells
A light-activatable bacteriophage T7 RNA polymerase (T7RNAP) has been generated through the site-specific introduction of a photocaged tyrosine residue at the crucial position Tyr639 within the active site of the enzyme.The photocaged tyrosine disrupts...
|
|
|
Pennsylvania Federal Court Upholds Union Health Benefit FundsEUR Claims Under Consumer Protection Law And Un
Pennsylvania Federal Court upheld a consumer class action brought by two Philadelphia Municipal union health and welfare benefit plans, to recover the money they and other health benefit and prescription plans paid for useless fentanyl pain patches that were...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
Yondelis(R) has been approved for soft tissue sarcoma (STS) in Israel, Panama and Ukraine.Additionally, the authorities in Paraguay and Azerbaijan have approved the drug for platinum-sensitive recurrent ovarian cancer (ROC). Yondelis(R) is currently...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
MADRID The European Commission approved Yondelis(R) for platinum-sensitive ROC in September 2009 In view of the three new approvals for STS, Yondelis(R) now has authorization for this indication in 25 countries outside the EEA: Argentina Clinical trials are...
|
|
|
When Choosing Antibiotic Regimen, Location Is Key
Miami Beach, Fla.-A three-drug regimen consisting of double gram-negative coverage plus methicillin-resistant Staphylococcus aureus (MRSA) coverage is a must for increasing the success of proper initial empiric antibiotic selection, according to a study...
|
|
|
NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference
(BUSINESS WIRE) ----NPS Pharmaceuticals, Inc.(Nasdaq: NPSP) announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the Barclays Capital 2010 Global Healthcare Conference in Miami, Florida on Tuesday,...
|
|
|
Yondelis Receives Five New Approvals Outside the European Economic Area
Yondelis(R) has been approved for soft tissue sarcoma (STS) in Israel, Panama and Ukraine.Additionally, the authorities in Paraguay and Azerbaijan have approved the drug for platinum-sensitive recurrent ovarian cancer (ROC). Yondelis(R) is currently...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Israel, Panama and Ukraine have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults.Furthermore, the authorities in...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Israel, Panama and Ukraine have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults.Furthermore, the authorities in...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Israel, Panama and Ukraine have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults.Furthermore, the authorities in...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Israel, Panama and Ukraine have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults.Furthermore, the authorities in...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Israel, Panama and Ukraine have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults.Furthermore, the authorities in...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Israel, Panama and Ukraine have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults.Furthermore, the authorities in...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Israel, Panama and Ukraine have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults.Furthermore, the authorities in...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Israel, Panama and Ukraine have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults.Furthermore, the authorities in...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Israel, Panama and Ukraine have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults.Furthermore, the authorities in...
|
|
|
Yondelis(R) Receives Five New Approvals Outside the European Economic Area
Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Israel, Panama and Ukraine have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults.Furthermore, the authorities in...
|
